Comparative study between tramadol (50 mg) on demand and paroxitine HCl (20 mg) on demand in the treatment of premature ejaculation

Eid, Mohamed; Ahmed, Hossam H.; Ismail, Nashaat Nabil; Shehada, Sameh Y.

doi:10.1097/01.xha.0000399371.38752.73

Cited by 8 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been an increasing trend toward the use of tramadol to treat PE with promising results. [ 1 11 12 13 14 15 16 17 18 19 20 21 22 23 24 ] The main possible two modes of action for treatment of PE are; binding to μ-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin. [ 19 ] In the current study, the aim was to evaluate both the effects and side-effects of oral tramadol HCl in two different (50 and 100 mg) doses versus placebo.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have shown that tramadol HCl oral therapy has yielded promising results in the treatment of PE. [ 1 11 12 13 14 15 16 17 18 19 20 21 22 23 24 ] It is still not clearly understood how tramadol delays ejaculation; however, several pharmacological studies have proposed some actions as; acting as μ-opioid agonist by the drug or its M1 metabolite,[ 25 ] 5-hydroxytryptamine type 2C receptor antagonist,[ 26 ] 5-nicotinic acetylcholine receptor antagonist,[ 27 ] N-methyl-D-aspartate receptor antagonist,[ 28 ] M1/M3 muscarinic receptor antagonist[ 29 30 ] and an inhibitor of serotonin/norepinephrine uptake. [ 31 ] Thus, the exact mechanism remains speculative, and it might be a combination of the fore mentioned mechanisms.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A randomized, double-blind, placebo-controlled, crossover trial of "on-demand" tramadol for treatment of premature ejaculation

et al. 2015

View full text Add to dashboard Cite

Objectives:The objective of this study is to assess the dose-related effects of tramadol on a group of patients with premature ejaculation (PE).Subjects and Methods:During the period of months between June 2010 and July 2012, 180 PE patients presented to outpatient clinic of our hospital. Patients were randomized in a 1:1:1 fashion to receive different sequences of the three medications: placebo, 50 mg of tramadol and 100 mg of tramadol. Every patient received 10 doses of each medication for 2 months. Intra-vaginal ejaculatory latency time (IELT) was recorded in seconds initially and for each arm. Successful treatment of PE is defined if IELT exceeded 120 s. Side-effects of medications were reported.Results:Of patients enrolled, 125 (69.4%) continued the study. Patients’ age range was 20-55 years with PE complaint of 1 to 10 years duration. Mean IELT was 72 at presentation, 82 for placebo, 150 for tramadol 50 mg, and 272 for tramadol 100 mg (P < 0.001 for all comparisons). PE was successfully treated in only 2.4% of patients with placebo, in contrast to 53.6% and 85.6% with 50 and 100 mg tramadol, respectively (P < 0.001 for all comparisons). On multivariate logistic regression analysis, baseline IELT was the only predictor of successful treatment of PE with both tramadol 50 mg (odds ratio [OR]: 1.05, 95% confidence interval [CI]: 1.03-1.07, P < 0.001) and tramadol 100 mg (OR: 1.07, 95% CI: 1.04-1.11, P < 0.001). Postmicturition dribble annoyed 12.8% of those who received 50 mg tramadol and 33.6% of those who received 100 mg tramadol (P < 0.001). Weak scanty ejaculation was the main complaint in 7.2% versus 21.6% of those using 50 and 100 mg tramadol, respectively (P = 0.002). Two patients discontinued tramadol 100 mg due to side-effects.Conclusion:Tramadol hydrochloride exhibits a significant dose-related efficacy and side-effects over placebo for treatment of PE.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A randomized, double-blind, placebo-controlled, crossover trial of "on-demand" tramadol for treatment of premature ejaculation

et al. 2015

View full text Add to dashboard Cite

show abstract

“…51,52 Tramadol has shown promising results in multiple studies examining its use in the medical management of patients with PE. [53][54][55][56][57][58] Khan et al showed a significant increase in IELT in patients that were treated with tramadol. 53 A comprehensive meta-analysis carried out by Wu et al showed an increase in IELT of 3 min when comparing tramadol with a placebo.…”

Section: Tramadolmentioning

confidence: 99%

“…It is thought that tramadol's effectiveness in the treatment of PE is due to the neuromodulation of serotonin and norepinephrine receptors . Tramadol has shown promising results in multiple studies examining its use in the medical management of patients with PE . Khan et al .…”

Section: Current Therapiesmentioning

confidence: 99%

Current and emerging therapies in premature ejaculation: Where we are coming from, where we are going

et al. 2016

View full text Add to dashboard Cite

Premature ejaculation is the most common form of sexual dysfunction among men. The pathophysiology of premature ejaculation appears to be multifactorial, implicating the need for multimodal therapeutic regimens to successfully treat premature ejaculation. Multiple treatment regimens have been shown to be effective in extending the time between penetration and ejaculation. These treatment modalities include everything from behavioral modifications and medications to diet alterations and major surgery. The goal of the present article was to review the commonly used treatment regimens used in the treatment of premature ejaculation, as well as to introduce and discuss the newest treatment routines under study for the treatment of premature ejaculation.

show abstract

“…It is thought that tramadol treats PE through the neuromodulation of serotonin and norepinephrine [48]. It has been shown by several studies to both increase IELT and sexual satisfaction in patients with PE [49][50][51]. Wu et al performed a meta-analysis and systematic review to assess the safety and efficacy of tramadol in the treatment of PE.…”

Section: Systemic Therapymentioning

confidence: 99%

Ejaculatory and Orgasmic Dysfunction Following Prostate Cancer Therapy: Clinical Management

2019

View full text Add to dashboard Cite

The majority of sexual health research has focused on erectile dysfunction following prostate cancer treatment. Ejaculatory and orgasmic dysfunction are significant side effects following the treatment of prostate cancer. Orgasmic dysfunction covers a range of issues including premature ejaculation, anorgasmia, dysorgasmia, and climacturia. This review provides an overview of prevalence and management options to deal with orgasmic dysfunction. A Medline Pubmed search was used to identify articles relating to these problems. We found that orgasmic dysfunction has a very large impact on patients’ lives following prostate cancer treatment and there are ways for physicians to treat it. Management of patients’ sexual health should be focused not only on erectile dysfunction, but on orgasmic dysfunction as well in order to ensure a healthy sexual life for patients and their partners.

show abstract

Comparative study between tramadol (50 mg) on demand and paroxitine HCl (20 mg) on demand in the treatment of premature ejaculation

Cited by 8 publications

References 12 publications

A randomized, double-blind, placebo-controlled, crossover trial of "on-demand" tramadol for treatment of premature ejaculation

A randomized, double-blind, placebo-controlled, crossover trial of "on-demand" tramadol for treatment of premature ejaculation

Current and emerging therapies in premature ejaculation: Where we are coming from, where we are going

Ejaculatory and Orgasmic Dysfunction Following Prostate Cancer Therapy: Clinical Management

Contact Info

Product

Resources

About